- Home
- MBOT vs VTVT Comparison
MBOT vs VTVT Comparison
Compare MBOT & VTVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MBOT | VTVT |
|---|---|---|
| Founded | 2010 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 126.3M | 127.0M |
| IPO Year | N/A | 2015 |
Fundamental Metrics
Financial Performance| Metric | MBOT | VTVT |
|---|---|---|
| Price | $2.28 | $34.17 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | $8.75 | ★ $37.00 |
| AVG Volume (30 Days) | ★ 3.0M | 12.6K |
| Earning Date | 11-12-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $17,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2,166.67 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.93 | $13.15 |
| 52 Week High | $4.67 | $35.95 |
Technical Indicators
Market Signals| Indicator | MBOT | VTVT |
|---|---|---|
| Relative Strength Index (RSI) | 48.70 | 72.05 |
| Support Level | $2.31 | $32.84 |
| Resistance Level | $2.55 | $35.95 |
| Average True Range (ATR) | 0.17 | 2.17 |
| MACD | 0.03 | 0.67 |
| Stochastic Oscillator | 59.15 | 97.41 |
Price Performance
Historical ComparisonAbout MBOT Microbot Medical Inc.
Microbot Medical Inc is a breakthrough medical device company. The group is focused on transforming endovascular procedures through advanced robotic technology. Microbot's LIBERTY Endovascular Robotic System is the first single-use, remotely operated robotic solution designed for precision, efficiency and provider safety. With a robust intellectual property portfolio and a deep commitment to innovation, Microbot is shaping the future of endovascular care.
About VTVT vTv Therapeutics Inc.
vTv Therapeutics Inc is a late-stage biopharmaceutical company focused on developing oral, small molecule drug candidates intended to help treat people living with diabetes and other chronic diseases. Its clinical pipeline is led by cadisegliatin, currently in a Phase 3 trial, a potential novel first-in-class oral liver-selective glucokinase activator being investigated for the treatment of type 1 diabetes. The group and its development partners are investigating multiple molecules across different indications for chronic diseases. Its product pipeline are HPP737, Azeliragon, TTP-RA, TTP273, HPP971 / HPP3033, and HPP593.